These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20303127)

  • 1. Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
    Pan J; Shilian P; Ishida B; Wu X; Kane JP; Malloy MJ; Charles MA
    Metabolism; 2011 Feb; 60(2):292-7. PubMed ID: 20303127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of physical exercise on plasma prebeta-1 high-density lipoprotein.
    Jafari M; Leaf DA; Macrae H; Kasem J; O'conner P; Pullinger C; Malloy M; Kane JP
    Metabolism; 2003 Apr; 52(4):437-42. PubMed ID: 12701055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
    Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma lipid concentrations and HDL subclasses.
    Yang Y; Yan B; Fu M; Xu Y; Tian Y
    Clin Chim Acta; 2005 Apr; 354(1-2):49-58. PubMed ID: 15748599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
    Plomgaard P; Dullaart RP; de Vries R; Groen AK; Dahlbäck B; Nielsen LB
    J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
    Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
    Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of weight reduction on the distribution of apolipoprotein A-I in high-density lipoprotein subfractions in obese non-insulin-dependent diabetic subjects.
    Shige H; Nestel P; Sviridov D; Noakes M; Clifton P
    Metabolism; 2000 Nov; 49(11):1453-9. PubMed ID: 11092511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hepatic HDL-related mRNAs on plasma prebeta HDL in cholesterol-fed rabbits.
    Sugano M; Makino N; Yanaga T
    Artery; 1997; 22(4):182-205. PubMed ID: 9576025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case report of a diabetic woman with very low HDL cholesterol.
    Chaychi L; Kinlaw WB; Asztalos BF; Schaefer EJ
    J Clin Lipidol; 2010; 4(2):133-5. PubMed ID: 21122641
    [No Abstract]   [Full Text] [Related]  

  • 11. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy.
    Sorrentino SA; Besler C; Rohrer L; Meyer M; Heinrich K; Bahlmann FH; Mueller M; Horváth T; Doerries C; Heinemann M; Flemmer S; Markowski A; Manes C; Bahr MJ; Haller H; von Eckardstein A; Drexler H; Landmesser U
    Circulation; 2010 Jan; 121(1):110-22. PubMed ID: 20026785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease.
    Guey LT; Pullinger CR; Ishida BY; O'Connor PM; Zellner C; Francone OL; Laramie JM; Naya-Vigne JM; Siradze KA; Deedwania P; Redberg RF; Frost PH; Seymour AB; Kane JP; Malloy MJ
    Am J Cardiol; 2011 Aug; 108(3):360-6. PubMed ID: 21757044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic effects of hypolipemic drugs on aged type 2 diabetes].
    Palel G; Coman A; Petrovanu R; Ungureanu D
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(3):518-20. PubMed ID: 12092185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between apolipoprotein C-III concentrations and high-density lipoprotein subclass distribution.
    Tian L; Wu J; Fu M; Xu Y; Jia L
    Metabolism; 2009 May; 58(5):668-74. PubMed ID: 19375590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.